Stem cell-based approaches have the potential to revolutionize drug discovery. However, many stem cell-related concepts are radically different from those of traditional R&D and as such, integrating these concepts into today’s drug discovery culture raises a number of scientific and organizational challenges.
This workshop will focus on key challenges and opportunities in stem cell-based drug discovery today. We will aim at identifying solutions that can make the use of stem cells a transformative approach to R&D.
Specifically, this workshop will look to bring together:
• Drug developers from leading pharmaceutical companies who will share their experience and expectations of stem cell-based models • Biotech representatives who will describe how emerging technologies will help facilitate the use of stem cells in R&D • Academic and government researchers who will bring their experience using stem cells for disease modeling, gene expression profiling and high-throughput screening
Attend this workshop to understand the latest developments in the field and take the information back to the lab to direct your research and development efforts.
Arnaud Lacoste, Project Team Leader, Stem Cells and Regenerative Medicine, Novartis
Arnaud is a Project Team Leader at Novartis where he has pioneered the use of reprogramming technologies and pluripotent stem cells.
Arnaud’s group combines reprogramming technologies, genome editing and large-scale production (multi-billion cell scale) of human iPSC-derived cell types to generate drug discovery models with unprecedented disease- and patientrelevance.
Prior to his appointment at Novartis, Arnaud was in charge of the Rockefeller University Embryonic Stem Cell and Reprogramming Facility in New York. This group served academic members of the New York Tri-Institutional Stem Cell Initiative including Cornell University, Rockefeller University and the Sloan- Kettering Cancer Center.